Evaluation of the expression of CD200 and CD56 in CD34-positive adult acute myeloid leukemia and its effect on the response to induction of chemotherapy

Muhsin, Zainab Najah; Al-Mudallal, Subh Salem

doi:10.4103/ijh.ijh_37_17

Cited by 8 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was in agreement with Tonks et al, 2007, which demonstrates expressing association of inv ( 16) (generally associated with FAB-M4 easo) with significantly overexpressed CD200 when compared to M4 patients without inv ( 16). These all conduct to CD200 is expressed more with monocytic differentiated AML than in myeloid differintiated AML which is in agreement with Muhsin et al, 2017 who found CD200 expressed more in monocytic subtypes (M4-M5), and found extramedullary manifestation more with CD200 positive expression. There was a statistically significant relation between CD200 postive expression and CD34 positive cases.…”

Section: Discussionsupporting

confidence: 90%

“…In respect to analysis of CD200 expression in 104 newly diagnosed AML patients in our study: CD200 positive expression (≥20%) was frequently detected in our patients (59.5%) patients. In comparison to 76.5% reported by Atfy et al, 2015 and 56%, 48%, 43%, 53.3% detected in studies by Damiani et al, 2015-Tiribelli et al, 2017-Tonks et al, 2007and Muhsin et al, 2017 respectively in AML. Also, in patients with precursor leukaemia lymphoma it was found CD200 positive expressed in (66%, 95 and 80.3%) reported by Aref et al, 2018-Alapat et al 2012and Awad et al, 2016 We can suggest CD200 be used as a minimal residual disease marker as well as for targeted antibody therapy, anti-CD200 antibody direct to CD200 + AML cells, this antibody-based therapy can stimulate cell phagocytosis to increase the possibility of AML curing and to limit AML relapse.…”

Section: Discussionmentioning

confidence: 52%

See 1 more Smart Citation

Significance of CD200 expression in patients with acute myeloid leukemia and its correlation with other prognostic markers

Rabea

Farawela

Soliman

et al. 2022

International Journal of Cancer and Biomedical Research

View full text Add to dashboard Cite

Background and Objectives: Acute myeloid leukemia (AML) known as cancer of blood and bone marrow is regarded as the commonest acute leukemia in adult patients. characterized by uncontrolled proliferation of hematopoietic progenitor cells with arrest of maturation and disruption of normal hematopoiesis. CD200 is a protein belonging to the immunoglobulin superfamily, it has an immunosuppressant effect by interacting with its receptor (CD200R). Aim: The main aim of this study is to investigate the expression of CD200 on leukemic myeloid cells. Various molecular prognostic markers and other clinical and laboratory findings were studied in relation to CD200 expression. Patients and Methods: The present study was conducted on newly diagnosed AML patients attending the adult Hematology/Oncology Clinic of the National Cancer Institute. The expression of CD200 was determined by flow cytometry using anti-CD200 monoclonal antibodies. CD200 expression considered positive if ≥20% and negative if <20%. Results: CD200 positive expression was found in 62/104 (59.5%) patients, CD200 was more expressed in CD34 positive cases (P= 0.012) and cases with gum hyperplasia (P= 0.046). FLT3/ITD mutation and NPM mutation were less detected in AML patients with positive CD200 (p=0.045 and p= 0.036 respectively). We found a statistically significant relation between inv16 and CD200 positive expression (p=0.005). Conclusion: CD200 could be used as a biological biomarker in AML pathophysiology, and could be incorporated in the initial diagnostic workup in patients treated within clinical trials for the discovery of new therapy which target malignant leukemic cells without harming other cells in AML.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 52%

Significance of CD200 expression in patients with acute myeloid leukemia and its correlation with other prognostic markers

Rabea

Farawela

Soliman

et al. 2022

International Journal of Cancer and Biomedical Research

View full text Add to dashboard Cite

show abstract

“…19,15 CD7 and TdT were both expressed in 10% of AML cases for each, most of the studies reported results higher than ours as for CD7 (43%, 40%, 33%, 18% and 12%). 4,14,[21][22][23] As for TdT, other studies reported frequencies of (6.2% and 15.4%) 8,24 CD19 was expressed 2.6% of AML cases in our study while most of the studies reported higher frequencies of (27%, 15.8% and 10.7%) 4,16,20 CD56 was expressed in 7.7% of AML cases in our study, the majority of studies reported higher frequencies (15% and 17.3%). 13,25 Aberrant expression in B-ALL The frequency of aberrant phenotype in B-ALL cases in the current study was 48.8% higher result of 71% was reported by Jalal et al while Ahuja and Malviya reported a frequency of 60%.…”

Section: Resultsmentioning

confidence: 99%

Evaluation of aberrant expression of CD markers in acute leukemia cells

kareem Shwani,

Sadiq Muhammad,

Hassan Hamza

2023

Zanco J Med Sci

View full text Add to dashboard Cite

Background and objective: Worldwide immunophenotyping by flow cytometry (FCM) in acute leukemia (AL) is the golden step in the diagnosis. It’s very common for acute leukemias to aberrantly express antigens or cluster of differentiation (CD) markers which are usually expressed in other lineages of the disease hence this study aimed at determining the prevalence of aberrancy in AL and to find out the frequency of each aberrant CD marker and their association with the clinic-hematological profile of the cases. Methods: Following history and clinical examination of enrolled patients, blood and/or bone marrow aspirate was drawn for morphological examination and immunophenotyping by FCM from 86 newly diagnosed acute leukemia cases then multiple steps procedure was applied followed by interpretation of the results. Results: The prevalence of aberrant phenotype was 46.5%. The proportional frequency of aberrant phenotype in acute myeloid leukemia (AML) was 41%, in B-acute lymphoblastic leukemia (B-ALL) was 48.8% and in T-acute lymphoblastic leukemia (T-ALL) was 66.6%. The commonest aberrant CD markers in AML were CD22 and CD2, in B-ALL were CD66c and CD13 while in T-ALL were CD13 and CD33. The aberrant phenotype harbored lower white blood cell (WBC) count and blast percentage in PB, also splenomegaly was more frequent in lymphoid positive (Ly+) AML and myeloid positive (My+) T-ALL while in B-ALL, splenomegaly was more frequent in myeloid negative (My-) B-ALL. Conclusion: Aberrant phenotype prevalence in our study sample was comparable to other studies, considerable frequency of aberrant markers is present in cases of AL and some variations exist regarding the clinical and hematological profile of the aberrant group.

show abstract

“…In the present study, aberrant expression of B markers in AML patients showed that CD79a was the most frequently expressed marker at 16.7% [15/90] of all AML patients, followed by CD10 and CD22 at 5.6% [5/90] and 1.1% [1/90], respectively, while expression of T marker CD7 in AML patients was 12.2% [11/90]. Other studies noted different distributions of aberrant marker expression, and many of them reported that CD7 was the most common lymphoidassociated antigen in AML, followed by CD19 [11,12] .…”

Section: Discussionmentioning

confidence: 99%

Detection of Aberrant Phenotypes in Acute Leukemia Patients in Relation to Some Hematological Parameters

Moustafa

Mahfouz

Mohamed

et al. 2023

International Journal of Medical Arts

View full text Add to dashboard Cite

Article informationBackground: Patients with acute leukemia [AL] may express aberrant antigens that are normally restricted to a different lineage. We evaluated the frequency of aberrancy in AL patients.Aim of the work: Evaluation and analysis of the incidence of aberrant phenotypes in mononuclear cells in AL patients and their relation to hematological parameters. Patients and Methods: This observational descriptive study was conducted on 150 newly diagnosed cases of AL over the period from August 2017 to March 2021. Flow cytometry was performed by Becton Dickinson [BD] FACS Calibur/BD FACS Canto flow cytometers using monoclonal antibodies against cell markers. Results: The overall frequency of aberrancy was 38.7% [58/150] in all AL patients. Aberrant antigenic expression was more frequent in acute lymphoblastic leukemia [ALL] than acute myeloid leukemia [AML], T-ALL with aberrant expression was 66.6% of all T-ALL patients, while B-ALL with aberrant expression was 45.8% of all B-ALL patients, and AML with aberrant expression was 31.1% of all AML patients. Conclusion: Aberrant phenotypes were found with considerable frequency in AL patients, and the implication of aberrant markers can help in disease monitoring, detecting measurable residual disease, and determining risk stratification and treatment intensity.

show abstract

Evaluation of the expression of CD200 and CD56 in CD34-positive adult acute myeloid leukemia and its effect on the response to induction of chemotherapy

Cited by 8 publications

References 2 publications

Significance of CD200 expression in patients with acute myeloid leukemia and its correlation with other prognostic markers

Significance of CD200 expression in patients with acute myeloid leukemia and its correlation with other prognostic markers

Evaluation of aberrant expression of CD markers in acute leukemia cells

Detection of Aberrant Phenotypes in Acute Leukemia Patients in Relation to Some Hematological Parameters

Contact Info

Product

Resources

About